Sfoglia per Autore
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)
2001 C., Bengala; I., Pazzagli; F., Innocenti; S., Donati; C., Favre; M. C., Menconi; F., Greco; R., Danesi; C., Orlandini; Guarneri, Valentina; M., Del Tacca; Conte, Pierfranco
New combinations with epirubicin in advanced breast cancer.
2001 Conte, Pierfranco; Gennari, A; Landucci, E; Guarneri, Valentina; Donati, S; Salvadori, B; Bengala, C; Orlandini, C.
Rischio neoplastico post-trapianto
2001 C., Bengala; Guarneri, Valentina; I., Pazzagli
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials
2001 Conte, Pierfranco; Gennari, A; Guarneri, Valentina; Landucci, E; Donati, S; Salvadori, B; Bengala, C; Orlandini, C; Baldini, E.
Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer
2002 Gennari, A; Guarneri, Valentina; Landucci, E; Orlandini, C; Rondini, M; Salvadori, B; Ricci, S; Conte, Pierfranco
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study
2003 C., Bengala; R., Danesi; Guarneri, Valentina; I., Pazzagli; S., Donati; C., Favre; S., Fogli; O., Biadi; F., Innocenti; M., DEL TACCA; M., Mariani; Conte, Pierfranco
Outcomes of metastatic breast cancer patients older than 60 years treated with FEC or ET regimens: A retrospective analysis
2003 A., Gennari; Guarneri, Valentina; C., Orlandini; B., Salvadori; S., Donati; M., Rondini; S., Ricci; E., Landucci; Conte, Pierfranco
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
2004 A., Gennari; P., Bruzzi; C., Orlandini; B., Salvadori; S., Donati; E., Landucci; Guarneri, Valentina; M., Rondini; S., Ricci; Conte, Pierfranco
Renal safety of zoledronic acid in patients with bone metastases from breast cancer (BC) or other tumors treated with IV BisphosphonateS (BPS) for up to ten years
2004 Guarneri, Valentina; Donati, S; Nicolini, M; Conte, Pierfranco
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial
2004 Conte, Pierfranco; Guarneri, Valentina; P., Bruzzi; T., Prochilo; B., Salvadori; A., Bolognesi; D., Aldrighetti; M., Venturini; R., Rosso; S., Mammoliti; F., Carnino; P., Giannessi; M., Costantini; A., Moyano; E., Baldini
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici
2004 Dominici, Massimo; Guarneri, Valentina; Cafarelli, Luigi; Conte, Pierfranco
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
2004 Conte, Pierfranco; Guarneri, Valentina
The curability of breast cancer and the treatment of advanced disease
2004 Guarneri, Valentina; Conte, Pierfranco
Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001
2004 A., Gennari; Conte, Pierfranco; C., Orlandini; Guarneri, Valentina; R., Rosso; P., Bruzzi; for the North West Oncology Group, Gono
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support
2004 Guarneri, Valentina; C., Bengala; C., Orlandini; A., Gennari; S., Donati; D., Campani; P., Collecchi; M., Maur; Conte, Pierfranco
Renal safety and efficacy of intravenous bisphosphonates in patients with skeletal metastases treated for up to ten years
2005 Guarneri, Valentina; S., Donati; M., Nicolini; S., Giovannelli; D'Amico, Roberto; Conte, Pierfranco
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens"
2005 Conte, Pierfranco; Guarneri, Valentina
In response to Jackson letter to the editor regarding "Safety of intravenous and oral bisphosphonates and compliance with dosing regimens"
2005 Conte, Pierfranco; Guarneri, Valentina
Prognostic value of pathologic complete response after primary chemotherapy in patients with hormone receptor-positive breast cancer.
2005 Guarneri, Valentina; K., Broglio; S., Kau; M., Cristofanilli; Au, Buzdar; V., Valero; T., Buchholz; F., Meric; L., Middleton; Gn, Hortobagyi; AM Gonzalez, Angulo
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma
2005 C., Bengala; Guarneri, Valentina; E., Giovannetti; M., Lencioni; E., Fontana; V., Mey; A., Fontana; U., Boggi; M., Del Chiaro; R., Danesi; S., Ricci; F., Mosca; M., Del Tacca; Conte, Pierfranco
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC) | 1-gen-2001 | C., Bengala; I., Pazzagli; F., Innocenti; S., Donati; C., Favre; M. C., Menconi; F., Greco; R., Danesi; C., Orlandini; Guarneri, Valentina; M., Del Tacca; Conte, Pierfranco | |
New combinations with epirubicin in advanced breast cancer. | 1-gen-2001 | Conte, Pierfranco; Gennari, A; Landucci, E; Guarneri, Valentina; Donati, S; Salvadori, B; Bengala, C; Orlandini, C. | |
Rischio neoplastico post-trapianto | 1-gen-2001 | C., Bengala; Guarneri, Valentina; I., Pazzagli | |
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials | 1-gen-2001 | Conte, Pierfranco; Gennari, A; Guarneri, Valentina; Landucci, E; Donati, S; Salvadori, B; Bengala, C; Orlandini, C; Baldini, E. | |
Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer | 1-gen-2002 | Gennari, A; Guarneri, Valentina; Landucci, E; Orlandini, C; Rondini, M; Salvadori, B; Ricci, S; Conte, Pierfranco | |
High – dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study | 1-gen-2003 | C., Bengala; R., Danesi; Guarneri, Valentina; I., Pazzagli; S., Donati; C., Favre; S., Fogli; O., Biadi; F., Innocenti; M., DEL TACCA; M., Mariani; Conte, Pierfranco | |
Outcomes of metastatic breast cancer patients older than 60 years treated with FEC or ET regimens: A retrospective analysis | 1-gen-2003 | A., Gennari; Guarneri, Valentina; C., Orlandini; B., Salvadori; S., Donati; M., Rondini; S., Ricci; E., Landucci; Conte, Pierfranco | |
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy | 1-gen-2004 | A., Gennari; P., Bruzzi; C., Orlandini; B., Salvadori; S., Donati; E., Landucci; Guarneri, Valentina; M., Rondini; S., Ricci; Conte, Pierfranco | |
Renal safety of zoledronic acid in patients with bone metastases from breast cancer (BC) or other tumors treated with IV BisphosphonateS (BPS) for up to ten years | 1-gen-2004 | Guarneri, Valentina; Donati, S; Nicolini, M; Conte, Pierfranco | |
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma - Results from the Gruppo Oncologico Nord Ovest randomized trial | 1-gen-2004 | Conte, Pierfranco; Guarneri, Valentina; P., Bruzzi; T., Prochilo; B., Salvadori; A., Bolognesi; D., Aldrighetti; M., Venturini; R., Rosso; S., Mammoliti; F., Carnino; P., Giannessi; M., Costantini; A., Moyano; E., Baldini | |
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici | 1-gen-2004 | Dominici, Massimo; Guarneri, Valentina; Cafarelli, Luigi; Conte, Pierfranco | |
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens | 1-gen-2004 | Conte, Pierfranco; Guarneri, Valentina | |
The curability of breast cancer and the treatment of advanced disease | 1-gen-2004 | Guarneri, Valentina; Conte, Pierfranco | |
Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001 | 1-gen-2004 | A., Gennari; Conte, Pierfranco; C., Orlandini; Guarneri, Valentina; R., Rosso; P., Bruzzi; for the North West Oncology Group, Gono | |
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support | 1-gen-2004 | Guarneri, Valentina; C., Bengala; C., Orlandini; A., Gennari; S., Donati; D., Campani; P., Collecchi; M., Maur; Conte, Pierfranco | |
Renal safety and efficacy of intravenous bisphosphonates in patients with skeletal metastases treated for up to ten years | 1-gen-2005 | Guarneri, Valentina; S., Donati; M., Nicolini; S., Giovannelli; D'Amico, Roberto; Conte, Pierfranco | |
In response to Body letter to the editor regarding "Safety of intravenous and oral Bisphosphonates and compliance with dosing regimens" | 1-gen-2005 | Conte, Pierfranco; Guarneri, Valentina | |
In response to Jackson letter to the editor regarding "Safety of intravenous and oral bisphosphonates and compliance with dosing regimens" | 1-gen-2005 | Conte, Pierfranco; Guarneri, Valentina | |
Prognostic value of pathologic complete response after primary chemotherapy in patients with hormone receptor-positive breast cancer. | 1-gen-2005 | Guarneri, Valentina; K., Broglio; S., Kau; M., Cristofanilli; Au, Buzdar; V., Valero; T., Buchholz; F., Meric; L., Middleton; Gn, Hortobagyi; AM Gonzalez, Angulo | |
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma | 1-gen-2005 | C., Bengala; Guarneri, Valentina; E., Giovannetti; M., Lencioni; E., Fontana; V., Mey; A., Fontana; U., Boggi; M., Del Chiaro; R., Danesi; S., Ricci; F., Mosca; M., Del Tacca; Conte, Pierfranco |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile